免疫抑制宿主重症肺炎诊治中国专家共识
中华医学会呼吸病学分会与中国抗癌协会肿瘤呼吸病学分会组织多学科专家,针对免疫抑制宿主重症肺炎的14个临床关键问题制定本共识。共识采用GRADE框架系统评价证据并形成推荐,涵盖免疫抑制定义与分类、诊断流程、病原分布、抗感染治疗、呼吸支持及免疫调节等方面,旨在规范临床实践。
要点
- 免疫抑制宿主指对病原体免疫反应显著减弱或缺失者,分原发性和继发性,需结合基础病与免疫指标评估。
- 重症肺炎诊断参照2016年中国CAP指南标准,此类人群可适当降低住院门槛(1C)。
- 经验性抗感染需覆盖耐药革兰阴性及阳性菌,肺移植或造血干细胞移植后双肺间质性肺炎可经验性覆盖巨细胞病毒(1A)。
核心结论
- 本共识为免疫抑制宿主重症肺炎的规范化诊疗提供建议,旨在支持循证决策并改善患者结局。
研究设计与样本
- 中华医学会呼吸病学分会与中国抗癌协会肿瘤呼吸病学分会组织呼吸与危重症、感染等领域多学科专家制定,采用GRADE框架系统评价证据并形成推荐,涵盖14个临床关键问题。
主要发现
- 免疫抑制宿主感染后进展为重症肺炎的风险显著高于免疫正常人群,且病死率更高。
- 免疫抑制宿主肺炎核心病原通常与免疫正常宿主相似,但病原分布更多样,机会性病原和混合感染更常见。
关键数值与推荐
- 免疫抑制宿主定义:因各种内在或外在因素导致对病原体免疫反应显著减弱或缺失,分原发性和继发性。
- 重症肺炎诊断依据2016年中国社区获得性肺炎(CAP)指南标准,初诊时评估疾病严重程度和免疫状态(1C)。
- 初始经验性治疗应覆盖耐药革兰阴性及阳性菌,存在危险因素时扩大覆盖(1A)。
- 呼吸机相关性肺炎(VAP)推荐含β-内酰胺类的联合方案(1A)。
- 侵袭性肺念珠菌病首选棘白菌素类,适当时可考虑换用唑类(1A)。
临床怎么用
- 疑诊感染后尽早采集高质量标本行微生物检测,采样方式个体化(1B)。
- 重症肺炎患者应在经验性治疗前或同时进行全面微生物检测(1A)。
- 经验性治疗选择需考虑免疫缺陷类型与程度、医疗暴露、耐药风险、感染严重度、微生物结果、治疗反应及预防策略(1A)。
- 不需立即插管的呼吸衰竭患者优先无创呼吸支持,可选经鼻高流量氧疗(HFNO)或无创正压通气(NPPV)(1A)。
- 有创通气撤机后可积极考虑早期拔管序贯NPPV或HFNO,无禁忌时NPPV可作为初始策略(1A)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The population of immunocompromised hosts has steadily increased in recent years. Clinical evidence indicates that these individuals are at a significantly higher risk of developing severe pneumonia following infection, with the mortality rates markedly higher than those observed in immunocompetent individuals. However, there is currently a lack of specific national or international guidelines or expert consensus addressing the management of severe pneumonia in this population. To address this unmet need, the Chinese Thoracic Society (CTS) of the Chinese Medical Association and the Oncology Respiratory Disease Committee of China Anti-Cancer Association (CACA) convened a multidisciplinary panel of experts from respiratory and critical care medicine, infectious diseases, and related fields in China to develop the present consensus.This consensus addresses 14 key clinical questions, covering topics such as the definition and classification of immunocompromised hosts, and the diagnosis and treatment of severe pneumonia in this high-risk group. The panel systematically reviewed evidence and formulated recommendations using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework. The resulting consensus aims to standardize clinical practice, support evidence-based decision-making, and eventually improve outcomes for immunocompromised patients with severe pneumonia in China.Question 1: Definition and classification of immunocompromised Hosts.Recommendation 1: An immunocompromised host is defined as a patient with a significantly weakened or absent immune response to pathogens owing to various intrinsic or extrinsic factors. The immunocompromised status is categorized as either primary or secondary. This assessment should integrate the patient's underlying conditions with available immunological parameters.Question 2: What are the diagnostic criteria for severe pneumonia in immunocompromised hosts, and which indicators are recommended for severity assessment?Recommendation 2: Severe pneumonia in immunocompromised hosts is diagnosed based on the criteria outlined by the 2016 Chinese guidelines for community-acquired pneumonia (CAP). Disease severity and immune status should be assessed at initial diagnosis to evaluate risk and guide treatment decisions. Hospitalization thresholds may be appropriately reduced in this population (1C).Question 3: What are the diagnostic and therapeutic workflows for severe pneumonia in immunocompromised hosts, and how should infectious pneumonia be distinguished from non-infectious pulmonary infiltrates?Recommendation 3: A multidimensional approach is recommended for differentiating severe pneumonia from non-infectious pulmonary infiltrates in immunocompromised hosts. Clinical, radiological, and microbiological data should be integrated. When necessary, histopathological biopsy and/or multidisciplinary team (MDT) consultation should be performed. The detailed diagnostic and therapeutic workflow are illustrated in Figure 1 (1A).Question 4: What are the major pathogens causing pneumonia in immunocompromised hosts, and how does pathogen distribution differ across immunosuppressive states?Recommendation 4: The core pathogens causing pneumonia in immunocompromised hosts are usually similar to those in immunocompetent hosts. However, pathogen distribution is more diverse, with immunocompromised hosts showing a higher prevalence of opportunistic pathogens and mixed infections (Table 5 and Figure 1A).Question 5: What are the recommended timings and methods for obtaining clinical specimens from immunocompromised hosts?Recommendation 5: High-quality clinical specimens are necessary for etiological diagnosis. Once infection is suspected, early sampling for microbiological testing is recommended. The sampling approach should be individualized based on the patient's condition and the clinical team's experience (1B).Question 6: How to choose diagnostic methods for pathogen identification in immunocompromised hosts with pneumonia?Recommendation 6: For immunocompromised hosts with severe pneumonia, comprehensive microbiological testing should be performed before or concurrently with empirical therapy to identify pathogens as early as possible and guide treatment strategies (1A).Question 7: What are the principles of anti-infective therapy for severe pneumonia in immunocompromised hosts?Recommendation 71. Initial empirical therapy should target drug-resistant Gram-negative and Gram-positive bacteria, with expansion of coverage when risk factors are present (1A).2. For ventilator-associated pneumonia (VAP), combination regimens that include β-lactams are recommended (1A).3. Echinocandins are preferred for treating invasive pulmonary candidiasis, and a switch to azoles may be considered when appropriate (1A).4. Empirical coverage for cytomegalovirus pneumonia is recommended for patients developing bilateral interstitial pneumonia shortly after lung transplantation or hematopoietic stem cell transplantation (1A).Question 8: What factors should be considered when selecting empirical anti-infective therapy for severe pneumonia in immunocompromised hosts?Recommendation 8: Empirical therapy should be selected based on the type and degree of immunodeficiency, healthcare exposure, risk of antimicrobial resistance, severity of infection, microbiological findings, treatment response, and preventive strategies (1A).Question 9: What are the recommended treatment durations for different pathogens in severe pneumonia among immunocompromised hosts?Recommendation 9: Treatment duration primarily depends on clinical presentation, radiographic changes, severity of infection, pathogen resistance profile, and the immune status of patients (1A).Question 10: Which respiratory support strategies should be prioritized for immunocompromised hosts with severe pneumonia complicated by respiratory failure?Recommendation 10: Noninvasive respiratory support is preferred for immunocompromised hosts with severe pneumonia and respiratory failure who do not require immediate intubation. High-flow nasal oxygen (HFNO) or noninvasive positive-pressure ventilation (NPPV) may be selected (1A).Question 11: When is tracheal intubation most appropriate for immunocompromised hosts with severe pneumonia?Recommendation 11: The timing of tracheal intubation in immunocompromised hosts is usually similar to that in immunocompetent hosts (1A).Question 12: When should extracorporeal membrane oxygenation (ECMO) be initiated in immunocompromised hosts with severe pneumonia and respiratory failure?Recommendation 12: The timing of ECMO initiation should be determined based on the same criteria as those used for immunocompetent hosts (1A).Question 13: For immunocompromised patients with severe pneumonia and respiratory failure, is early extubation followed by NPPV or HFNO a viable option?Recommendation 13: Early extubation followed by NPPV or HFNO can be actively considered for immunocompromised patients with severe pneumonia complicated by respiratory failure. In the absence of contraindications to NPPV, NPPV may be attempted as the initial post-extubation strategy (1A).Question 14: What recommendations are there for immunomodulatory therapy in immunocompromised hosts with severe pneumonia?Recommendation 14: Immunomodulation is an important component of therapy in immunocompromised hosts with severe pneumonia. Immune status should be assessed to guide individualized immunoregulatory strategies (1B). 近年来,免疫抑制宿主在临床实践中日益常见,大量临床研究表明,免疫抑制宿主感染后进展为重症肺炎的风险显著高于免疫正常人群,且病死率更高。由于目前国内外尚缺乏针对免疫抑制宿主重症肺炎的诊疗指南和专家共识,中华医学会呼吸病学分会联合中国抗癌协会肿瘤呼吸病学分会,组织国内呼吸与危重症和感染领域相关专家制定了本共识。本共识包含免疫抑制宿主的定义与分类、免疫抑制宿主重症肺炎的诊断和治疗相关的14个临床关键问题,为免疫抑制宿主重症肺炎的规范化诊疗提供建议。.
引用
- [Chinese expert consensus on the diagnosis and treatment of severe pneumonia in immunocompromised hosts]. Zhonghua Jie He He Hu Xi Za Zhi. 2026. PMID: 41629088. doi:10.3760/cma.j.cn112147-20250729-00449
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。